How many patients with severe sepsis are needed to confirm the efficacy of drotrecogin alfa activated? A Bayesian design

被引:0
作者
Andre C. Kalil
Junfeng Sun
机构
[1] University of Nebraska Medical Center,Department of Internal Medicine
[2] University of Nebraska,Department of Biostatistics, College of Public Health
[3] 985400 Nebraska Medical Center,undefined
来源
Intensive Care Medicine | 2008年 / 34卷
关键词
Severe sepsis; Drotrecogin alfa activated; Bayesian methodology;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 219 条
[1]  
Deans KJ(2005)Mechanical ventilation in ARDS: one size does not fit all Crit Care Med 33 1141-1143
[2]  
Minneci PC(2006)Drotrecogin alfa (activated): down and not out, but not really in either Crit Care 10 420-1626
[3]  
Cui X(2006)When a single pivotal trial should not be enough-the case of drotrecogin-alfa (activated) Intens Care Med 32 604-2428
[4]  
Banks SM(2005)Activated protein C: do more survive? Intens Care Med 31 1624-204
[5]  
Natanson C(2005)Reassessing recombinant human activated protein C for sepsis: time for a new randomized controlled trial Crit Care Med 33 2426-1030
[6]  
Eichacker PQ(2005)Struggle for implementation of new strategies in intensive care medicine: anticoagulation, insulin, and lower tidal volumes J Crit Care 20 199-709
[7]  
Friedrich JO(2002)Risks and benefits of activated protein C treatment for severe sepsis N Engl J Med 347 1027-470
[8]  
Adhikari NK(2001)Efficacy and safety of recombinant human activated protein C for severe sepsis N Engl J Med 344 699-762
[9]  
Meade MO(2001)Recombinant human activated protein C reduced all-cause mortality in patients with severe sepsis ACP J Club 135 81-1037
[10]  
Wiedermann CJ(2003)Canadian Association of General Surgeons Evidence Based Reviews in Surgery. 8. Efficacy and safety of recombinant human activated protein C for severe sepsis Can J Surg 46 468-1341